To clinically validate the expression of NCL on human NB, immunophenotype staining of patient-derived primary tumor cells and BM-infiltrating NB cells, firstly validated by cytomorphology evaluation, was carried out. This evidence concerns the gene NUCLEOLIN and neuroblastoma.